Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03002935 · ClinicalTrials.gov registry record · Phase 1
A Safety Study of Orally Administered BPM31510 in Healthy Subjects
A Phase 1 study, sponsored by BPGbio.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT03002935: Completed Phase 1 study, sponsored by BPGbio.
NCT03002935 is a Phase 1 study that has completed, run by BPGbio. The registered enrollment target is 25 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (58% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03002935, a Phase 1 study, has completed, sponsored by BPGbio.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
This is an open-label, Phase I study of the bioavailability and safety of BPM31510 administered orally in healthy subjects dosed 3 times daily for 14 days. The last study dose is administered on Day 15 (one morning dose only). The study will consist of 25 subjects.
Primary Outcome
Pharmacokinetic (PK) samples collected to establish oral bioavailability.
Interventions
- DRUG BPM31510 Oral Nanosuspension 4%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2017-01 |
| Est. Completion | 2017-03 |
| Phase | Phase 1 |
What the finished NCT03002935 record still lists
NCT03002935 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (58% lower).
The record links to 0 conditions, and to 1 intervention - of which BPM31510 Oral Nanosuspension 4% is the first listed.
NCT03002935 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03002935 about?
NCT03002935 is a clinical study titled "A Safety Study of Orally Administered BPM31510 in Healthy Subjects". This is an open-label, Phase I study of the bioavailability and safety of BPM31510 administered orally in healthy subjects dosed 3 times daily for 14 days. The last study dose is administered on Day 15 (one morning dose only). The study will consist of 25 subjects.
What is the current status of trial NCT03002935?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2017-01. Estimated completion is 2017-03.
What interventions are being tested in trial NCT03002935?
The interventions under investigation include: BPM31510 Oral Nanosuspension 4% (DRUG).
Who is sponsoring clinical trial NCT03002935?
This trial is sponsored by BPGbio, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03002935's enrollment target sits among peer trials
25 1495th of 2000 higher than 481 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia